- Stocks
- Pharma & Healthcare
- Amrutanjan Health Care
Amrutanjan Health Care share price
NSE: AMRUTANJANPharma & HealthcareDrug Manufacturers - Specialty & Generic
Amrutanjan Health Care at a glance
Amrutanjan Health Care (NSE: AMRUTANJAN) closed at ₹501.00 on 19 Oct 2026, down 3.09% on the day. With a market capitalisation of ₹1,448 Cr, it ranks 1297th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 25× trailing earnings, against a return on equity of 16.8% in FY17. Over the past year the share price has fallen 28.8%. Its 52-week range is ₹476.50 (16 Sep 2026) to ₹760.15 (29 Oct 2025); the last close is 34.1% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹150 Cr (+10.6% year on year) and net profit ₹16 Cr (+6.7%), on a standalone basis. Promoters held 46.52% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹1,448 CrRank 1297 on NSE
- P/E (trailing)
- 25×
- Price to book
- 6.85×FY17
- EPS (TTM)
- ₹20.03to Q4 FY26
- ROE
- 16.8%FY17
- ROCE
- 23.9%FY17
- Debt to equity
- 0.02FY17
- Net profit margin
- 9.4%FY17
- Book value / share
- ₹86.22FY17
- 52-week high
- ₹760.1529 Oct 2025
- 52-week low
- ₹476.5016 Sep 2026
- 1-year return
- −28.8%
- RSI (14-day)
- 45.8
Returns to 19 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −3.09% | −0.8% | +2.1% | −8.7% | −28.8% |
Amrutanjan Health Care quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹84 Cr | ₹110 Cr | ₹123 Cr | ₹135 Cr | ₹94 Cr | ₹118 Cr | ₹141 Cr | ₹150 Cr |
| Revenue YoY | +7.6% | +10.7% | +4.9% | +6.6% | +12.3% | +7.1% | +14.9% | +10.6% |
| Net profit | ₹5 Cr | ₹12 Cr | ₹19 Cr | ₹15 Cr | ₹8 Cr | ₹14 Cr | ₹19 Cr | ₹16 Cr |
| Net profit YoY | −34.1% | +72.3% | +10.3% | +11.1% | +79.9% | +18.3% | +1.0% | +6.7% |
| Net margin | 5.5% | 10.7% | 15.7% | 11.2% | 8.8% | 11.9% | 13.8% | 10.8% |
| EPS | ₹1.60 | ₹4.08 | ₹6.66 | ₹5.25 | ₹2.87 | ₹4.83 | ₹6.73 | ₹5.60 |
Amrutanjan Health Care financials
| Item | FY12 | FY13 | FY14 | FY15 | FY16 | FY17 |
|---|---|---|---|---|---|---|
| Revenue | ₹143 Cr | ₹138 Cr | ₹142 Cr | ₹167 Cr | ₹187 Cr | ₹224 Cr |
| Operating profit | ₹16 Cr | ₹15 Cr | ₹19 Cr | ₹24 Cr | ₹33 Cr | ₹31 Cr |
| Net profit | ₹10 Cr | ₹10 Cr | ₹12 Cr | ₹15 Cr | ₹21 Cr | ₹21 Cr |
| EPS (₹) | ₹32.00 | ₹7.00 | ₹9.00 | ₹10.00 | ₹14.00 | ₹14.00 |
| Cash from operations | ₹4 Cr | ₹9 Cr | ₹17 Cr | ₹18 Cr | ₹21 Cr | ₹0 Cr |
| Total debt | ₹6 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹96 Cr | ₹82 Cr | ₹89 Cr | ₹95 Cr | ₹109 Cr | ₹126 Cr |
Amrutanjan Health Care shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 46.52% | 46.52% | 46.52% | 46.52% | 46.52% | 46.52% |
| Foreign institutions | 2.30% | 2.41% | 2.38% | 2.27% | 2.17% | 2.44% |
| Domestic institutions | 11.41% | 12.70% | 12.90% | 13.00% | 12.66% | 12.28% |
| Non-institutions | 39.74% | 38.33% | 38.16% | 38.18% | 38.61% | 38.72% |
Amrutanjan Health Care vs peers
The listed Pharma & Healthcare companies nearest to Amrutanjan Health Care by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ASTECAstec LifeSciences | ₹693.00 | −2.05% | −10.0% | ₹1,544 Cr | — | — |
| GKSLGujarat Kidney And Super Speciality | ₹188.00 | +0.40% | — | ₹1,482 Cr | 75.5 | — |
| AMRUTANJANAmrutanjan Health Care | ₹501.00 | −3.09% | −28.8% | ₹1,448 Cr | 25 | — |
| JAGSNPHARMJagsonpal Ser | ₹217.95 | −0.07% | −1.3% | ₹1,435 Cr | 34.5 | — |
| AHCLAnlon Healthcare | ₹26.92 | −0.22% | +108.5% | ₹1,431 Cr | 44.1 | — |
| TTKHLTCARETTK Healthcare | ₹1,007.60 | −2.93% | −12.2% | ₹1,424 Cr | 21.7 | — |
| SHALBYShalby | ₹126.00 | −2.33% | −49.9% | ₹1,361 Cr | 38.9 | — |
Ask anything about Amrutanjan Health Care
Pivot answers on the live chart with evidence you can check, and tests strategies against AMRUTANJAN's own history. Try: “Why has AMRUTANJAN moved over the last three months?” · “Backtest a 50-day moving-average crossover on AMRUTANJAN over five years” · “Compare AMRUTANJAN with ASTEC on margins and valuation”
Frequently asked questions about Amrutanjan Health Care
What is the share price of Amrutanjan Health Care today?
Amrutanjan Health Care (NSE: AMRUTANJAN) last closed at ₹501.00 on 19 Oct 2026. Its 52-week high is ₹760.15 and its 52-week low is ₹476.50.
What is the market cap of Amrutanjan Health Care?
Amrutanjan Health Care's market capitalisation is ₹1,448 Cr (₹1,448 Cr) at the 19 Oct 2026 close, ranking 1297th among the NSE companies Pivot tracks.
What is the P/E ratio of Amrutanjan Health Care?
Amrutanjan Health Care trades at a trailing P/E of 25. The median P/E of the 5 closest Pharma & Healthcare peers by market cap is 38.9.
What is the ROE and ROCE of Amrutanjan Health Care?
Return on equity was 16.8% in FY17 and return on capital employed was 23.9% in FY17 (consolidated figures).
Is Amrutanjan Health Care a debt-free company?
Amrutanjan Health Care is close to debt-free: its debt-to-equity ratio was 0.02 in FY17.
What were Amrutanjan Health Care's latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Amrutanjan Health Care reported revenue of ₹150 Cr, +10.6% year on year, and net profit of ₹16 Cr, +6.7% year on year.
How has Amrutanjan Health Care stock performed over the last year?
Amrutanjan Health Care's share price has fallen 28.8% over the past year, −8.7% over three months and +2.1% over one month, to the 19 Oct 2026 close.
What is the shareholding pattern of Amrutanjan Health Care?
As of 30 Jun 2026: promoters 46.52%, foreign institutions 2.44%, domestic institutions 12.28%, non-institutions 38.72%.
Who are Amrutanjan Health Care's competitors?
The listed Pharma & Healthcare companies closest to Amrutanjan Health Care by market cap are Astec LifeSciences, Gujarat Kidney And Super Speciality, Jagsonpal Ser, Anlon Healthcare, TTK Healthcare and Shalby.
Is Amrutanjan Health Care a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Amrutanjan Health Care's price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on AMRUTANJAN against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 19 Oct 2026 (returns and ratios at the 19 Oct 2026 close). Fundamentals: company filings via Moneycontrol, standalone where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with A · all NSE stocks · this page as text